Clinical Trials Browser

Thyroid Cancer, Papillary, Astrocytoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02982694 2025-10-01

Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer

Phase 2 Terminated

46 enrolled

Gastrointestinal

Colorectal Neoplasms, Activated Protein C Resistance

NCT05350501 2025-09-29

CLAUDE

Phase 2 Terminated

1 enrolled 12 charts

Gastrointestinal

Colorectal Neoplasms

NCT05678257 2025-09-12

A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

Phase 2 Terminated

180 enrolled 16 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT00766142 2025-08-29

COCHISE

Phase 2 Terminated

18 enrolled 9 charts

GastrointestinalGynecologic

Colonic Neoplasms, Peritoneal Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05619172 2025-07-24

A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer

Phase 2 Terminated

16 enrolled 29 charts

Gastrointestinal

Colorectal Neoplasms

NCT05563272 2025-07-10

STARBURST

Phase 2 Terminated

11 enrolled

CNSGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma

NCT04786600 2025-07-01

A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial

Phase 2 Terminated

6 enrolled 11 charts

Gastrointestinal

Colorectal Neoplasms

NCT05330429 2025-07-01

ELEVATE CRC

Phase 2 Terminated

77 enrolled 22 charts

Gastrointestinal

Colorectal Neoplasms

NCT04853043 2025-05-06

APK Mutant

Phase 2 Terminated

7 enrolled 15 charts

Gastrointestinal

Colorectal Neoplasms

NCT03610490 2025-04-17

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Phase 2 Terminated

16 enrolled 11 charts

GastrointestinalGynecologic

Ovarian Neoplasms, Colorectal Neoplasms

NCT04383210 2025-04-03

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Phase 2 Terminated

54 enrolled 11 charts

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Fibromatosis, Gingival, 2, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Uterine Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04450836 2025-03-30

SOREGATT

Phase 2 Terminated

234 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04952753 2025-03-26

daNIS-3

Phase 2 Terminated

204 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT00961571 2025-02-12

Sunitinib and Capecitabine for First Line Colon Cancer

Phase 2 Terminated

50 enrolled 7 charts

Gastrointestinal

Colorectal Neoplasms

NCT03047837 2025-01-27

ASAMET

Phase 2 Terminated

160 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04258111 2024-11-18

IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer

Phase 2 Terminated

4 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05039944 2024-07-18

SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies

Phase 2 Terminated

7 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT02842580 2024-07-10

HIGH-LIGHT

Phase 2 Terminated

21 enrolled 12 charts

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT02581059 2024-06-26

Efficacy of Ginseng for Patients on Regorafenib

Phase 2 Terminated

10 enrolled 19 charts

Gastrointestinal

Fatigue, Colorectal Neoplasms

NCT05609656 2024-06-03

ELI

Phase 2 Terminated

4 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04854434 2023-11-03

A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations

Phase 2 Terminated

13 enrolled 14 charts

Gastrointestinal

Colorectal Neoplasms

NCT04171700 2023-10-02

LODESTAR

Phase 2 Terminated

83 enrolled 16 charts

BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinosarcoma, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Leiomyosarcoma, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT00601198 2023-08-01

A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer

Phase 2 Terminated

4 enrolled 9 charts

Gastrointestinal

Colorectal Neoplasms

NCT04515394 2022-12-22

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

Phase 2 Terminated

3 enrolled 6 charts

Gastrointestinal

Deafness, Autosomal Recessive 39, Colorectal Neoplasms

NCT01759238 2022-07-01

OLGA

Phase 2 Terminated

1 enrolled

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT01507545 2022-05-06

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Phase 2 Terminated

154 enrolled 13 charts

Gastrointestinal

Colorectal Neoplasms

NCT03099486 2022-02-07

Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC

Phase 2 Terminated

2 enrolled 7 charts

Gastrointestinal

Colorectal Neoplasms

NCT00321100 2022-01-12

Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab

Phase 2 Terminated

23 enrolled 8 charts

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT03050814 2021-12-20

Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004

Phase 2 Terminated

30 enrolled 15 charts

Gastrointestinal

Turcot syndrome, Colorectal Neoplasms

NCT01505166 2021-11-01

FANG-CLM

Phase 2 Terminated

3 enrolled 9 charts

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT02173990 2021-10-20

PULSAR

Phase 2 Terminated

40 enrolled

Gastrointestinal

Adenocarcinoma, Colorectal Neoplasms

NCT00314353 2021-10-06

Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon

Phase 2 Terminated

7 enrolled 5 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT02448810 2021-05-25

Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer

Phase 2 Terminated

115 enrolled 22 charts

Gastrointestinal

Colorectal Neoplasms

NCT00005944 2021-02-17

Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer

Phase 2 Terminated

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT03368859 2021-02-09

A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab

Phase 2 Terminated

70 enrolled 12 charts

Gastrointestinal

Intestinal Neoplasms, Neoplasms, Colorectal Neoplasms

NCT00986440 2020-11-05

Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy

Phase 2 Terminated

84 enrolled 14 charts

Gastrointestinal

Colorectal Neoplasms

NCT03724253 2020-10-23

NeoFIND

Phase 2 Terminated

19 enrolled 33 charts

BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT03549338 2020-09-28

Sym004 Versus Futuximab or Modotuximab in Patients With mCRC

Phase 2 Terminated

2 enrolled 9 charts

Gastrointestinal

Carcinoma, Colorectal Neoplasms

NCT02652702 2020-07-07

STAPLER

Phase 2 Terminated

60 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT00602329 2020-04-28

MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer

Phase 2 Terminated

5 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT02141295 2020-03-25

McCAVE

Phase 2 Terminated

197 enrolled 24 charts

Gastrointestinal

Colorectal Neoplasms

NCT01057017 2020-02-17

First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras

Phase 2 Terminated

5 enrolled 7 charts

Gastrointestinal

Colorectal Neoplasms

Clinical Trials

NeuroPrevPTSD

VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer

CLAUDE

A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

COCHISE

A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer

STARBURST

A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial

ELEVATE CRC

APK Mutant

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

SOREGATT

daNIS-3

Sunitinib and Capecitabine for First Line Colon Cancer

ASAMET

IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer

SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies

HIGH-LIGHT

Efficacy of Ginseng for Patients on Regorafenib

ELI

A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations

LODESTAR

A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

OLGA

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC

Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab

Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004

FANG-CLM

PULSAR

Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon

Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer

Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer

A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab

Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy

NeoFIND

Sym004 Versus Futuximab or Modotuximab in Patients With mCRC

STAPLER

MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer

McCAVE

First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras